A phase III trial of Imigliptin Dihydrochloride for the treatment of diabetes mellitus

Trial Profile

A phase III trial of Imigliptin Dihydrochloride for the treatment of diabetes mellitus

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Imigliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2016 New trial record
    • 29 Mar 2016 According to a Sihuan Pharmaceutical Holdings Group media release, application for the conduct of a phase II trial has been made to the China Food and Drug Administration (CFDA) and acceptance notice was received in September 2015. The on-site inspection has been completed on October 2015 and the approval is expected in a near term.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top